AVE(688067)

Search documents
爱威科技(688067) - 爱威科技关于选举第五届董事会职工代表董事的公告
2025-09-16 10:01
证券代码:688067 证券简称:爱威科技 公告编号: 2025-037 爱威科技股份有限公司 关于选举第五届董事会职工代表董事的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连带责任。 特此公告。 爱威科技股份有限公司董事会 2025 年 9 月 17 日 附件: 林常青先生简历 林常青先生,1972 年出生,中国国籍,无境外永久居留权,工商管理硕士。 1996 年 7 月至 2001 年 4 月就职于赛福尔集团公司,从事企业管理和投资项目管理 工作;2001 年 4 月至 2004 年 11 月担任爱威有限副总经理、董事会秘书;2004 年 11 月至 2008 年 2 月担任长沙怡海置业有限公司销售总监;2008 年 2 月至 2009 年 12 月担任湖南万容科技股份有限公司副总经理、董事会秘书;2010 年 2 月至 2012 年 9 月担任爱威有限副总经理、董事会秘书;2012 年 9 月至 2019 年 4 月担任公司 董事、副总经理、董事会秘书、财务总监;2019 年 4 月至 2021 年 10 月担任公司 ...
爱威科技(688067) - 爱威科技关于对外投资设立控股子公司的自愿性披露公告
2025-09-16 10:01
证券代码:688067 证券简称:爱威科技 公告编号:2025-038 爱威科技股份有限公司关于对外投资设立 控股子公司的自愿性披露公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏,并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 投资标的名称:湖南爱威光学科技有限公司(以下简称"爱威光学") 根据《上海证券交易所科创板股票上市规则》《公司章程》及相关制度 的规定,本次对外投资在公司总经理审批权限内,并已履行内部决策程序,无 需提交董事会、股东大会审议。 本次对外投资不构成关联交易,亦不构成《上市公司重大资产重组管理 办法》规定的重大资产重组情形。 本次设立爱威光学是基于公司的整体战略发展规划的布局,爱威光学在 经营过程中面临着宏观经济及行业政策变化、经营管理、技术研发、市场开发 等方面的风险因素,可能影响到公司前期投入的回收和预期效益的实现。 一、对外投资概述 (一)本次交易概况 1、本次交易概况 基于公司的整体战略发展规划和实际经营需求,公司与长沙酷当共同投资设 立湖南爱威光学科技有限公司。截至本公告披露日,爱威光学已完成工商注册登 记手续并取得营业执 ...
爱威科技(688067.SH):出资600万元与长沙酷当投资设立爱威光学
Ge Long Hui A P P· 2025-09-16 09:50
Group 1 - The core viewpoint of the article is that Awei Technology (688067.SH) has established a joint venture, Hunan Awei Optical Technology Co., Ltd., with Changsha Kudan to enhance its optical technology capabilities and supply chain security [1] - The investment aims to achieve self-controllable and domestically produced optical technologies, which will strengthen the company's competitive advantage in core technologies [1] - Awei Optical has a registered capital of RMB 10 million, with Awei Technology contributing RMB 6 million (60%) and Changsha Kudan contributing RMB 4 million (40%) through intellectual property [1]
爱威科技:设立湖南爱威光学科技有限公司,注册资本1000万元
Xin Lang Cai Jing· 2025-09-16 09:44
爱威科技公告,公司与长沙酷当共同投资设立湖南爱威光学科技有限公司。爱威光学注册资本人民币 1000万元,其中公司以自有资金出资600万元,占爱威光学注册资本的60%;长沙酷当以知识产权出资 400万元,占爱威光学注册资本的40%。 ...
爱威科技(688067) - 爱威科技关于参加2025年湖南辖区上市公司投资者网上集体接待日暨半年度业绩说明会活动的公告
2025-09-12 08:15
证券代码:688067 证券简称:爱威科技 公告编号: 2025-036 爱威科技股份有限公司董事会 2025 年 9 月 13 日 关于参加 2025 年湖南辖区上市公司投资者网上集体接 待日暨半年度业绩说明会活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连带责任。 为进一步加强与投资者的互动交流,爱威科技股份有限公司(以下简称"公司") 将参加由湖南证监局、湖南省上市公司协会与深圳市全景网络有限公司联合举办的 "资本聚三湘 楚光耀新程一一 2025 年湖南辖区上市公司投资者网上集体接待日暨 半年度业绩说明会"活动,现将相关事项公告如下: 本次活动将采用网络远程的方式举行,投资者可登录"全景路演"网站 (https://rs.p5w.net),或关注微信公众号:全景财经,或下载全景路演 APP,参 与本次互动交流,活动时间为 2025 年 9 月 19 曰(星期五)14:00-17:00。届时公 司高管将在线就公司 2024 年至 2025 半年度业绩、公司治理、发展战略、经营状况、 融资计划、股权激励和可持续发展等 ...
2025年中国生殖医学设备行业发展历程、市场政策、产业链图谱、市场规模、竞争格局及发展趋势研判:国产生殖医学设备占比达55.11%[图]
Chan Ye Xin Xi Wang· 2025-09-05 01:37
Overview - The global infertility rate is rising, leading to increased demand for assisted reproductive technology (ART) and driving the growth of the reproductive medical equipment market in China [1][13] - Changing fertility concepts, delayed childbearing age, and heightened awareness of reproductive health are expanding the market opportunities for reproductive medical devices [1][13] - The aging population and government encouragement for having more children are further stimulating demand for reproductive medical equipment [1][13] - The market size of China's reproductive medical equipment industry is projected to reach 9.69 billion yuan in 2024, with a year-on-year growth of 9.86% [1][13] Market Policies - The Chinese government has issued various policies to support the development of the medical device industry, including reproductive medical equipment [7] - Policies aim to strengthen management, enhance innovation, and promote high-quality development in the medical device sector [7] Industry Chain - The upstream of the reproductive medical equipment industry includes suppliers of chemical materials, biological medical materials, electronic components, and software systems [9] - The midstream involves the research, design, and production of reproductive medical devices [9] - The downstream consists of public hospitals, private reproductive centers, and patients who benefit from these medical devices [9][11] Competitive Landscape - Historically, imported brands dominated the high-end market of reproductive medical devices in China, but domestic companies are increasingly closing the technology gap [13][14] - By 2024, domestic reproductive medical devices are expected to account for 55.11% of the market share, indicating a shift from reliance on imports to domestic alternatives [13][14] Company Analysis - Suzhou Beikang Medical Co., Ltd. focuses on reproductive health product development and achieved a revenue of 299 million yuan in 2024, with a gross profit margin of 45.54% [14][15] - Awei Technology Co., Ltd. specializes in clinical medical testing equipment and achieved a revenue of 203 million yuan in 2024, with 97.74% coming from medical device sales [15] Development Trends - Future advancements in reproductive medical devices will focus on greater intelligence, automation, and personalization, driven by technologies like gene editing and artificial intelligence [15][16] - Domestic companies are expected to continue improving their technological capabilities and market recognition, leading to an accelerated process of domestic substitution in the market [15][16]
爱威科技(688067) - 爱威科技2025年第一次临时股东大会会议资料
2025-09-04 08:15
爱威科技股份有限公司 2025 年第一次临时股东大会会议资料 爱威科技股份有限公司 2025年第一次临时股东大会会议资料 | 2025年第一次临时股东大会会议须知 | | --- | | 2025年第一次临时股东大会会议议程 . | | 议案一:《关于变更经营范围、取消监事会、修订<公司章程>并办理相应工 | | 商变更登记的议案》 | | 沙安二 | 爱威科技股份有限公司 2025 年第一次临时股东大会会议资料 爱威科技股份有限公司 2025年第一次临时股东大会会议须知 二〇二五年九月 五、股东或股东代理人要求发言时,不得打断会议报告人的报告或其他股东的 发言,在股东大会进行表决时,股东或其代理人不再进行发言。股东或其代理人违 反上述规定,会议主持人有权加以拒绝或制止。 1 爱威科技股份有限公司 2025 年第一次临时股东大会会议资料 六、主持人可安排公司董事、监事、高级管理人员回答股东或股东代理人所提 问题。对于可能将泄露公司商业秘密及/或内幕信息,损害公司、股东共同利益的提 问,主持人或其指定有关人员有权拒绝回答。 为维护全体股东的合法权益,确保股东大会的正常秩序和议事效率,保证大会 的顺利进行,根据《 ...
爱威科技2025年中报简析:营收净利润同比双双增长
Zheng Quan Zhi Xing· 2025-08-29 22:42
Financial Performance - The company reported a total revenue of 110 million yuan for the first half of 2025, representing a year-on-year increase of 12.7% [1] - The net profit attributable to shareholders reached 14.0554 million yuan, up 21.16% year-on-year [1] - The gross profit margin was 56.34%, a slight decrease of 0.63% compared to the previous year, while the net profit margin increased by 7.51% to 12.83% [1] - The total of selling, administrative, and financial expenses was 37.2037 million yuan, accounting for 33.96% of revenue, down 6.17% year-on-year [1] - Earnings per share rose to 0.21 yuan, a 23.53% increase year-on-year [1] Business Model and Market Position - The company primarily relies on research and development and marketing to drive its performance [3] - It is a leader in the automation of urine analysis and has a significant market share in this segment, with competitors including Dirui, Mindray, and others [5] - The company has begun to focus on the consumer healthcare market, launching various POCT products aimed at women's health, child health, and other areas, indicating a potential growth direction [6] Technology and Innovation - The company is a pioneer in applying artificial intelligence and machine vision technology to medical urine specimen analysis, significantly improving testing accuracy and efficiency [7] - It has developed a large clinical specimen training database over 25 years, enhancing its algorithm for specimen recognition [7] Future Plans - The company is considering new projects and potential mergers and acquisitions to drive growth, as indicated in its 2024 annual report [8]
爱威科技: 爱威科技关于召开2025年第一次临时股东大会的通知
Zheng Quan Zhi Xing· 2025-08-29 16:29
证券代码:688067 证券简称:爱威科技 公告编号:2025-033 爱威科技股份有限公司 关于召开2025年第一次临时股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏,并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示: (三) 投票方式:本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 召开地点:湖南省长沙市岳麓区学士街道茯苓路 26 号公司 319 会议室 涉及融资融券、转融通业务、约定购回业务相关账户以及沪股通投资者的投 票,应按照《上海证券交易所科创板上市公司自律监管指引第 1 号 — 规范运作》 等有关规定执行。 (七) 涉及公开征集股东投票权 无 二、 会议审议事项 本次股东大会审议议案及投票股东类型 投票股东类型 序号 议案名称 A 股股东 非累积投票议案 司章程>并办理相应工商变更登记的议案》 上述议案已经公司第五届董事会第五次会议审议通过,具体内容详见公司同日在 上海证券交易所网站(www.sse.com.cn)及公司指定披露媒体披露的相关公告。 应回避表决的关联股东名称:无 ? 股东大会召开日期:2025年9月 ...
爱威科技: 爱威科技第五届监事会第五次会议决议公告
Zheng Quan Zhi Xing· 2025-08-29 16:29
Group 1 - The Supervisory Board of the company held its fifth meeting on August 28, 2025, with all three members present, and the meeting complied with relevant laws and regulations [1][2]. - The Supervisory Board approved the company's 2025 semi-annual report, confirming that the report's preparation and review processes adhered to legal requirements and accurately reflected the company's financial status and operational results [1][2]. - The Supervisory Board also approved a special report on the storage and actual use of raised funds, affirming that the funds were stored in dedicated accounts and used appropriately, with no violations of regulations [2][3]. Group 2 - The Supervisory Board approved a proposal to change the company's business scope, cancel the Supervisory Board, and amend the Articles of Association, which aligns with the latest legal requirements and aims to enhance the company's governance structure [2][3]. - The proposal to cancel the Supervisory Board will be submitted for approval at the company's shareholders' meeting, and until then, the Supervisory Board will continue to fulfill its responsibilities [3].